3月25日,药明生物在港交所发布财报,2024年营收186.75亿元,同比增长9.6%;净利润33.6亿元,同比下降1.3%。公司拥有人应占经调整纯利47.8亿元,同比增长1.8%。 公告称,收益增长乃主要由于成功执行集团的“跟随并赢得分子”战略,领先的技术平台、行业最佳的项目交付时间及优秀的项目执行过往记录,为集团收益增长作出贡献;扩大为生物药行业提供服务的范围、快速发展的技术平台(包括 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.